$LUMO News
Last published 1y ago
- 1y agoANNXLUMOGRAYAviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of DirectorsBusiness WireAviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™)
- 1y agoLUMOLumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos PharmaGlobeNewswireAUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare
- 1y agoLUMOUpdated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of ActionGlobeNewswireAUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its
- 2y agoLUMOLumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024GlobeNewswireAUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the
- 2y agoFSHPICCHLUMOMMLPKuehn Law Encourages MMLP, ICCH, FSHP, and LUMO Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoLUMOLumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)GlobeNewswireAUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today
- 2y agoLUMOLumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024GlobeNewswireAUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data
- 2y agoLUMOLumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024GlobeNewswireAUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data
- 2y agoLUMOLumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireAUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in
- 2y agoLUMOLumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLUMOLumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development UpdateGlobeNewswireFollowing Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in
- 2y agoLUMOLumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024GlobeNewswireAUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024
- 2y agoLUMOLumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024GlobeNewswireAUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data
- 2y agoLUMOLumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024GlobeNewswireAUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its
- 2y agoLUMOLumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLUMOLumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsGlobeNewswireOutcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves
- 2y agoLUMOLumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024GlobeNewswireAUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial
- 2y agoLUMOLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsGlobeNewswireAUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 2y agoLUMOLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042GlobeNewswireAUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 2y agoLUMOLumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLUMOLumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateGlobeNewswireEnd of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met
- 2y agoLUMOLumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024GlobeNewswireAUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 2y agoLUMOLumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences ConferenceGlobeNewswireAUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced
- 2y agoLUMOLumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical OfficerGlobeNewswireAUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit "Duke" Pitukcheewanont, MD, known
- 2y agoLUMOLumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyGlobeNewswireAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced
- 2y agoLUMOLumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberGlobeNewswireAUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate
- 3y agoLUMOLumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development UpdatesGlobeNewswire-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6
- 3y agoLUMOLumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary EndpointsGlobeNewswireOraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD PopulationDelta at 6 and
- 3y agoLUMOLumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual MeetingGlobeNewswireDeconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children Analysis Shows Annualized Height Velocity Increased ~62% Compared to BaselineData Support LUM-201 Mechanism
- 3y agoLUMOLumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual MeetingGlobeNewswireAUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through
- 3y agoLUMOLumos Pharma Announces Participation in Investor Conferences in SeptemberGlobeNewswireAUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through
- 3y agoLUMOIndependent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic LandscapeGlobeNewswireAUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through
- 3y agoLUMOLumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical UpdateGlobeNewswireConfirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023Encouraging Interim Data from OraGrowtH Trials Presented at
- 3y agoLUMOLumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023GlobeNewswireAUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 3y agoLUMOLumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences SummitGlobeNewswireAUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 3y agoLUMOLumos Pharma Announces Departure of Chief Medical OfficerGlobeNewswireAUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through
- 3y agoLUMOLumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL WebinarGlobeNewswireWebinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos
- 3y agoLUMOLumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare ConferenceGlobeNewswireAUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 3y agoLUMOLumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21stGlobeNewswireAUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through
- 3y agoLUMOLumos Pharma to Participate in World Orphan Drug Congress USAGlobeNewswireAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through
- 3y agoLUMOEncouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)GlobeNewswireOral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural
- 3y agoLUMOLumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesGlobeNewswire-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials ---- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 ---- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 –--
- 3y agoLUMOData from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)GlobeNewswireOral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos
- 3y agoLUMOLumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023GlobeNewswireAUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 3y agoLUMOA Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial - NCT05796440ClinicalTrials.govIncidence of treatment-emergent adverse events, Growth Hormone Concentrations in subjects, Insulin-like growth factor 1 concentration, (and 4 more...)
- 3y agoLUMOLumos Pharma to Participate in Oppenheimer's 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023GlobeNewswireAUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2
- 3y agoLUMOAdditional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric EndocrinologyGlobeNewswireOral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation
- 3y agoLUMOLumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development UpdatesGlobeNewswire-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 -- -- Additional Data from OraGrowtH Trials to be Presented at
- 3y agoLUMOLumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHDGlobeNewswirePhase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.
- 3y agoLUMOLumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023GlobeNewswireAUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2